Multiple Sclerosis Clinical Research Trials

Active

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis

  • Status:Enrolling
  • Sponsor: Mallinckrodt
  • Click here for more information

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with Glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis

  • Status:Closed to Enrolling
  • Sponsor: Novartis Pharmaceuticals
  • Click here for more information

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy (PASSAGE)

  • Status:Closed to Enrolling
  • Sponsor: Novartis Pharmaceuticals
  • Click here for more information